MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Subscribe To Our Newsletter & Stay Updated
